Evidence guide · South Africa
MOTS-c: the 'exercise mimetic' peptide, the mouse data and the missing human trials
MOTS-c is one of six peptides in the October 2026 US compounding policy. What the mouse studies, the small trial of a modified version and the human exercise studies show, and why it is banned in sport.
Review type: research summary. This page summarises published research and product labels, cited below.
MOTS-c is one of the six peptides named in the US Department of Health and Human Services (HHS) compounding policy announced in the Federal Register on 30 October 2026, alongside BPC-157, epitalon, KPV, Semax and TB-500. It is sold online as a "research" peptide. A 2021 study in breast cancer survivors describes it as a mitochondrial derived peptide with exercise mimetic activity. It is also a molecule the body makes itself: a short peptide encoded in the DNA of mitochondria, the energy-producing parts of cells.
Short answer: the case for MOTS-c rests on mouse studies, several of them led by the scientists who discovered it and who disclosed links to a company developing a modified version of it. No randomised trial of MOTS-c itself in people has been published. The one placebo-controlled human trial was of a modified version, CB4211, made by that company, and it involved 20 people with fatty liver for four weeks in its main phase. In small human studies, exercise raised the body's own MOTS-c in some groups. An injection from an online seller is a different matter: none of these studies describes what such vials contain, and athletes should know MOTS-c is banned in sport at all times.
What MOTS-c is
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It was described in Cell Metabolism in 2015 by a team at the University of Southern California and the US National Institute on Aging as a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. In their experiments its main target organ appeared to be skeletal muscle. Its cellular actions inhibited the folate cycle and the de novo purine synthesis tethered to it, which led to activation of AMPK, an enzyme that acts as a cellular energy sensor. A 2018 paper from the same laboratory reported that, under metabolic stress, MOTS-c moves into the cell nucleus and regulates nuclear genes, including antioxidant-response genes, in an AMPK-dependent way.
Those papers disclose commercial links. In the 2015 paper, senior author Pinchas Cohen was a stockholder of and consultant for CohBar, Inc., and first author Changhan Lee was a consultant for it. CohBar developed CB4211, which it describes as an analogue of MOTS-c. The 2018 paper and the 2021 Nature Communications, Aging and Scientific Reports papers declare consulting or shareholding links to CohBar for Changhan Lee or Pinchas Cohen. The Journal of Applied Physiology paper declares no such link.
What the evidence says
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies), Insufficient (too little human research to judge) and Evidence of harm. Animal and cell studies do not count towards a grade.
Weight, insulin and metabolism: Insufficient
In the 2015 Cell Metabolism study, MOTS-c treatment in mice prevented insulin resistance linked to age and to a high-fat diet, and prevented diet-induced obesity. Seven days of injections (5 mg per kg of body weight a day into the abdominal cavity) restored insulin-stimulated glucose uptake in soleus muscle from 12-month-old male mice to levels comparable to younger mice. These were short studies in male laboratory mice.
The only placebo-controlled human data come from CB4211. The trial, registered as NCT03998514, was sponsored by CohBar and completed in April 2021 with 88 participants enrolled. Its primary outcomes were safety measures: adverse events, laboratory values, vital signs, heart tracings, physical examinations and injection-site reactions. No results are posted on ClinicalTrials.gov, and no peer-reviewed report of the trial is indexed in PubMed.
CohBar's own topline results, filed with the US Securities and Exchange Commission on 10 August 2021, describe a first phase in 65 healthy adults over one week to choose a dose, then a four-week phase in 20 people with obesity and non-alcoholic fatty liver disease who lived in the study unit throughout. On 25 mg a day injected under the skin (11 people) against placebo (9 people), fasting glucose fell by 6% against 0%. ALT fell by 21% while it rose by 4% on placebo, and AST fell by 28% against 11% on placebo. Body weight showed only a trend. Liver fat, measured by MRI, fell by a similar amount in both groups: 5.03 percentage points on CB4211 and 4.88 on placebo. The company reported no serious adverse events in either phase, and in the four-week phase the only adverse events in more than 10% of people on CB4211 were transient, generally mild to moderate injection-site reactions. These were exploratory measures in a very small trial, and CB4211 is not the MOTS-c sold online.
Exercise capacity and ageing: Insufficient
A 2021 Nature Communications study from the same research group is the main source of the anti-ageing claims. Daily injections improved treadmill running in middle-aged (12-month) and old (22-month) male mice: old treated mice ran about twice as long and 2.16 times as far as untreated old mice. Starting at about 23.5 months of age, injections three times a week improved grip strength, gait and physical performance late in life. The effect on lifespan was not conclusive: the authors report a trend towards longer median (6.4%) and maximum (7.0%) lifespan, with an overall p-value of 0.23, and write that larger cohorts will be needed to confirm the broader significance of MOTS-c treatment on overall longevity.
A 2026 review in Frontiers in Pain Research, added to PubMed on 14 November 2026, describes pain-relieving effects of MOTS-c across several animal models of nerve, diabetic, inflammatory and cancer-related bone pain. Its evidence is preclinical, and the authors frame mitochondrial-derived peptides as targets for future research.
What human studies have measured
The human studies of MOTS-c measure the body's own peptide. They do not give it to people.
- In the 2021 Nature Communications paper, 10 sedentary healthy young men cycled on a stationary bike. MOTS-c in their skeletal muscle rose 11.9-fold after exercise relative to their own starting values, and levels in the blood rose 1.6-fold during and 1.5-fold after exercise, returning to baseline after four hours of rest.
- A Swedish study in 30 adults (Journal of Applied Physiology, 2021) found that 45 minutes of cycling raised blood levels of humanin, another mitochondrial-derived peptide, while MOTS-c showed only a trend to increase. Resistance exercise did not raise either, and blood levels were not related to fitness.
- In a secondary analysis of a 16-week aerobic and resistance exercise trial in breast cancer survivors (Scientific Reports, 2021), MOTS-c rose in non-Hispanic White women but not in Hispanic women (24 and 25 women included in the analysis).
- A mitochondrial DNA variant called m.1382A>C, described as Asian-specific, changes one amino acid of MOTS-c (K14Q). A meta-analysis of three cohorts of Japanese ancestry, 27,527 people in all, including Japanese-Americans living in the United States, linked the variant to a higher prevalence of type 2 diabetes in men but not women (Aging, 2021). In the Japan Multi-Institutional Collaborative Cohort, the higher prevalence applied only to men in the least physically active third. This is genetic association evidence, and it does not show that taking MOTS-c would help anyone.
Safety in people: Insufficient
There is no published human safety study of MOTS-c itself. The CB4211 results cover a different molecule, given for at most four weeks, in a supervised research unit. According to the HHS policy, the US Food and Drug Administration (FDA) had placed MOTS-c, with the other five peptides, in its "Category 2" of bulk drug substances that may present significant safety risks from September 2023 until 22 April 2026, and the FDA's drug centre had recommended against adding it to the list of substances pharmacies may compound. HHS's own justification document points to a randomised, placebo-controlled trial of an analogue of MOTS-c rather than MOTS-c itself, and calls the FDA's safety concerns about several of these peptides "mechanistic" or "inferential rather than observed". That means the human safety record is thin, not that it is reassuring.
Sport: banned at all times
The 2026 World Anti-Doping Agency Prohibited List names "mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)" in section S4.4.1, among activators of AMPK, alongside AICAR. Substances in that section are prohibited in and out of competition. Any athlete subject to anti-doping rules who injects MOTS-c risks a violation.
Our view
- MOTS-c is real and scientifically interesting: a signal from mitochondria that responds to exercise. The published studies that gave MOTS-c itself were in mice.
- There is no published randomised trial of MOTS-c in people. The one placebo-controlled trial used a company's modified version for four weeks in 20 people, and its liver-fat result was no better than placebo.
- Where human studies have reported a rise in the body's own MOTS-c, the intervention was exercise: an 11.9-fold rise in skeletal muscle in 10 young men, only a trend after cycling in another study, and a rise limited to non-Hispanic White breast cancer survivors after 16 weeks.
- Do not inject MOTS-c bought online. The studies above do not describe the contents, strength or sterility of vials sold online, and it is banned in sport.
- If you are interested in metabolic health or healthy ageing, talk to your doctor about measures with human evidence, and ask about clinical trials rather than self-sourcing peptides.
South African rules
The US policy has no legal effect in South Africa. SAHPRA warns about the growing sale of unregistered peptide products promoted for uses including anti-ageing and enhanced performance, sold through online platforms, social media, gyms, wellness centres and informal suppliers. Its list of examples names other peptides, not MOTS-c, but its rule is general: under the Medicines and Related Substances Act 101 of 1965, any product intended to treat, prevent or alter bodily functions must be registered with SAHPRA before it can be sold. SAHPRA warns against self-administration without medical supervision, especially for products bought online. Report side effects to adr@sahpra.org.za.
FAQ
Is MOTS-c a supplement?
No. It is an unapproved peptide drug substance sold mostly as a powder for injection. It is not an approved medicine in the US, the UK, the UAE or South Africa.
Does MOTS-c help with weight loss?
There is no human trial of MOTS-c for weight loss. In mice it prevented diet-induced obesity. A company's modified version, CB4211, showed only a trend towards lower body weight over four weeks in 20 people with fatty liver.
Can exercise raise MOTS-c?
In small studies, yes. Cycling raised MOTS-c in the muscle and blood of 10 young men, and a 16-week exercise programme raised blood levels in some breast cancer survivors. Another study saw only a trend after cycling.
Is MOTS-c banned in sport?
Yes. The 2026 WADA Prohibited List names MOTS-c under S4.4.1, so it is prohibited at all times.
Sources
These are the documents this page relies on.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454Cell Metabolism (PubMed 25738459, PMC4350682)
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524Cell Metabolism (PubMed 29983246)
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470Nature Communications (PubMed 33473109, PMC7817689)
- von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol. 2021;131(3):1035-1042Journal of Applied Physiology (PubMed 34351816)
- Dieli-Conwright CM, Sami N, Norris MK, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep. 2021;11(1):16916Scientific Reports (PubMed 34413391)
- Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717Aging (PubMed 33468709)
- Wang Z, Liao J, Lu P, et al. Mitochondrial-derived peptides: emerging therapeutic targets at the intersection of mitochondrial dysfunction and pain. Front Pain Res. 2026;7:2006909Frontiers in Pain Research (PubMed 43032139)
- A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514)ClinicalTrials.gov
- CohBar announces positive topline results from the Phase 1a/1b study of CB4211 under development for NASH and obesity (press release, 10 August 2021, filed as Exhibit 99.2 to Form 8-K)CohBar, Inc. via US Securities and Exchange Commission (EDGAR)
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 2026)US Department of Health and Human Services
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket HHS-OASH-2026-0496. Federal Register 91(209):68526-68527, 30 October 2026Federal Register (GovInfo)
- Category 2 of the bulk substances nominated under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (content current as of 22 April 2026)US Food and Drug Administration
- World Anti-Doping Code International Standard: Prohibited List 2026 (section S4.4.1)World Anti-Doping Agency
- Peptide products: public informationSAHPRA